Will NVO's earnings momentum continue into 2024?

Novo Nordisk's earnings momentum is likely to continue into 2024, driven by several key factors:

1. Strong Financial Performance: Novo Nordisk reported a net profit of $3.92 billion and total revenue of $11.89 billion for Q4 2024. The company's net income grew by 20.22% year-over-year, while total revenue increased by 21.68%.

1/3

NVO Net Income YoY, Total Revenue YoY...

2. Growth Drivers: The company's diabetes and obesity care segments were the key drivers of growth, with obesity care segment seeing a 57% growth. The GLP-1 diabetes segment contributed significantly, with Ozempic®, Rybelsus®, and Victoza® dominating the market.
3. Strategic Investments: Novo Nordisk has been investing in R&D and supply chain expansions, which are set to continue in 2025. These investments are likely to pay off in the coming years, sustaining the company's growth trajectory.
4. Market Position: Novo Nordisk maintains a strong market position in the diabetes value market, with a share of 33.7%. The company's leadership, coupled with its innovative products, positions it well for continued success.
5. Analyst Confidence: The consensus rating for Novo Nordisk is a "Strong Buy" with an average analyst price target that suggests a potential upside from the current price. This indicates that analysts are optimistic about the company's future performance.

1/2

6. Potential Challenges: Despite the positive outlook, there are potential challenges such as competition from other drugmakers and the need to meet earnings expectations. Bank of America has lowered its price target, indicating a potential near-term miss in the first quarter due to slower sales of Wegovy and Ozempic. However, the full-year outlook remains positive.

In conclusion, while there may be some short-term challenges, Novo Nordisk's strong financial performance, growth drivers, strategic investments, and market position suggest that its earnings momentum is likely to continue into 2024.